Medical technology company Angle has unveiled results for a pilot study undertaken for a blood test which can detect and capture cancer cells. The technology, named Parsortix, was shown to be successful in both determining whether the patient had prostate cancer and whether the disease was in an early or later stage.
Parsortix captures tumour cells by circulating a blood sample through a cassette with multiple microscopic layers. The layers allow normal cells through but not tumour cells as these are larger. The trapped tumour cells can then be analysed in a lab.
This new test is much more accurate than the current test using prostate-specific antigen (PSA). Parsortix managed to identify 100% of late-stage cancer and 75% of early stage cancer. The test can also help to determine severity which is currently determined by an invasive biopsy.
The next stage for Parsortix is through clinical trials using several hundred people to check for accuracy of results and get regulatory approval.
The findings were announced on Friday at the International Symposium on Minimal Residue Cancer in Hamburg with the results expected to be published in a scientific journal within the next six months.
Find out more here.